A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease

Paul S. Aisen, Susan Egelko, Howard Andrews, Ramon Diaz-Arrastia, Myron Weiner, Charles DeCarli, William Jagust, Joshua W. Miller, Ralph Green, Karen Bell, Mary Sano

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.

Original languageEnglish (US)
Pages (from-to)246-249
Number of pages4
JournalAmerican Journal of Geriatric Psychiatry
Volume11
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Homocysteine
Vitamins
Alzheimer Disease
Fasting
Vitamin B 6
Vitamin B 12
Folic Acid
Double-Blind Method
Methionine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Aisen, P. S., Egelko, S., Andrews, H., Diaz-Arrastia, R., Weiner, M., DeCarli, C., ... Sano, M. (2003). A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. American Journal of Geriatric Psychiatry, 11(2), 246-249. https://doi.org/10.1097/00019442-200303000-00016

A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. / Aisen, Paul S.; Egelko, Susan; Andrews, Howard; Diaz-Arrastia, Ramon; Weiner, Myron; DeCarli, Charles; Jagust, William; Miller, Joshua W.; Green, Ralph; Bell, Karen; Sano, Mary.

In: American Journal of Geriatric Psychiatry, Vol. 11, No. 2, 2003, p. 246-249.

Research output: Contribution to journalArticle

Aisen, PS, Egelko, S, Andrews, H, Diaz-Arrastia, R, Weiner, M, DeCarli, C, Jagust, W, Miller, JW, Green, R, Bell, K & Sano, M 2003, 'A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease', American Journal of Geriatric Psychiatry, vol. 11, no. 2, pp. 246-249. https://doi.org/10.1097/00019442-200303000-00016
Aisen, Paul S. ; Egelko, Susan ; Andrews, Howard ; Diaz-Arrastia, Ramon ; Weiner, Myron ; DeCarli, Charles ; Jagust, William ; Miller, Joshua W. ; Green, Ralph ; Bell, Karen ; Sano, Mary. / A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. In: American Journal of Geriatric Psychiatry. 2003 ; Vol. 11, No. 2. pp. 246-249.
@article{0d908dd83d714fedbfbf2ff6e3e4ffc5,
title = "A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease",
abstract = "Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.",
author = "Aisen, {Paul S.} and Susan Egelko and Howard Andrews and Ramon Diaz-Arrastia and Myron Weiner and Charles DeCarli and William Jagust and Miller, {Joshua W.} and Ralph Green and Karen Bell and Mary Sano",
year = "2003",
doi = "10.1097/00019442-200303000-00016",
language = "English (US)",
volume = "11",
pages = "246--249",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease

AU - Aisen, Paul S.

AU - Egelko, Susan

AU - Andrews, Howard

AU - Diaz-Arrastia, Ramon

AU - Weiner, Myron

AU - DeCarli, Charles

AU - Jagust, William

AU - Miller, Joshua W.

AU - Green, Ralph

AU - Bell, Karen

AU - Sano, Mary

PY - 2003

Y1 - 2003

N2 - Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.

AB - Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.

UR - http://www.scopus.com/inward/record.url?scp=20244361897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244361897&partnerID=8YFLogxK

U2 - 10.1097/00019442-200303000-00016

DO - 10.1097/00019442-200303000-00016

M3 - Article

C2 - 12611755

AN - SCOPUS:20244361897

VL - 11

SP - 246

EP - 249

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 2

ER -